We are on a mission to make finger-prick blood glucose testing obsolete for people living with diabetes.
More than 170 million people in the Asia Pacific region are living with diabetes – that’s 38 percent of people with diabetes globally.
Through innovative technology, our goal is to free people living with diabetes from painful and invasive blood monitoring devices, giving them a better quality of life.
GBS Inc. is a biosensor diagnostic technology company focused on commercializing the Saliva Glucose Biosensor the Asia Pacific Region, including Australia, Indonesia, Japan and New Zealand. GBS Inc.
GBS Inc. is a proud member of The iQ Group Global, a group of companies committed to creating the medicines of the future. What starts here changes the world.
SYDNEY – May 29, 2020 The iQ Group Global has announced a collaboration with Harvard University to develop a printable point-of-care SARS-CoV-2 antibody test for the COVID-19 disease that could […]
The world’s first non-invasive, saliva-based glucose test for diabetes management SYDNEY – February , 2019 – The iQ Group Global, a consortium of life science and financial services companies which […]
The Saliva Glucose Biosensor
Replacing finger-pricks for people living with diabetes
The Saliva Glucose Biosensor is the first pain-free, non-invasive replacement for finger-prick blood glucose testing.
Through the regulatory process, we intend to demonstrate that the Saliva Glucose Biosensor can be used as a point of care test indicated for the management of diabetes, as non-adjunctive to blood glucose testing for diabetes treatment decisions.
For illustrative purposes only and has yet to receive regulatory approval in any jurisdiction.